Ivashchenko Yuri, Kramer Frank, Schäfer Stefan, Bucher Andrea, Veit Kerstin, Hombach Vinzenz, Busch Andreas, Ritzeler Olaf, Dedio Jürgen, Torzewski Jan
Aventis Pharma Deutschland GmbH, DG Cardiovascular Research, Frankfurt am, Germany.
Arterioscler Thromb Vasc Biol. 2005 Jan;25(1):186-92. doi: 10.1161/01.ATV.0000150041.81963.68. Epub 2004 Nov 11.
C-reactive protein (CRP) is the prototype acute phase protein and a cardiovascular risk factor. Interleukin-1beta (IL-1beta) and IL-6 stimulate CRP synthesis in hepatocytes. We searched for additional pathways regulating CRP expression.
Primary human hepatocytes (PHHs) were treated with IL-1beta, IL-6, and protein kinase C (PKC) activator phorbol 12,13-dibutyrate (PDBu). CRP was analyzed by quantitative RT-PCR and ELISA. PDBu significantly induced CRP transcription by 21.0+/-9.24-fold and protein release by 2.9+/-0.5-fold. Transcriptional regulation was studied in detail in hepatoma G2 (HepG2) cells stably transfected with the 1-kb CRP promoter (HepG2-ABEK14 cells). In these cells, PDBu significantly induced CRP transcription by 5.39+/-0.66-fold. Competitive inhibition with bisindolylmaleimide derivative LY333531 abolished PDBu-mediated promoter activation. Competitive inhibition with IkappaB kinase inhibitor I229 also inhibited PDBu effects. Importantly, IL-8 significantly induced CRP release in PHHs by 58.675+/-19.1-fold, which was blockable by LY333531.
This study describes a novel PKC-dependent transcriptional regulation of CRP gene expression, which, in analogy to the classical IL-1beta and IL-6 pathways, is operational in hepatocytes only. It also identifies IL-8 as a potential physiological PKC activator. HepG2-ABEK14 cells may be useful for high throughput screening to identify inhibitors of CRP synthesis for the prevention of cardiovascular disease.
C反应蛋白(CRP)是急性期蛋白的原型,也是一种心血管危险因素。白细胞介素-1β(IL-1β)和IL-6可刺激肝细胞合成CRP。我们寻找调节CRP表达的其他途径。
用IL-1β、IL-6和蛋白激酶C(PKC)激活剂佛波醇12,13 - 二丁酸酯(PDBu)处理原代人肝细胞(PHH)。通过定量逆转录聚合酶链反应(RT-PCR)和酶联免疫吸附测定(ELISA)分析CRP。PDBu显著诱导CRP转录增加21.0±9.24倍,蛋白释放增加2.9±0.5倍。在稳定转染1 kb CRP启动子的肝癌G2(HepG2)细胞(HepG2-ABEK14细胞)中详细研究转录调控。在这些细胞中,PDBu显著诱导CRP转录增加5.39±0.66倍。双吲哚马来酰亚胺衍生物LY333531的竞争性抑制消除了PDBu介导的启动子激活。IκB激酶抑制剂I229的竞争性抑制也抑制了PDBu的作用。重要的是,IL-8显著诱导PHH中CRP释放增加58.675±19.1倍,这可被LY333531阻断。
本研究描述了一种新的依赖PKC的CRP基因表达转录调控,类似于经典的IL-1β和IL-6途径,仅在肝细胞中起作用。它还将IL-8鉴定为潜在的生理性PKC激活剂。HepG2-ABEK14细胞可能有助于高通量筛选,以鉴定用于预防心血管疾病的CRP合成抑制剂。